登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>B7-H4 >B74-C52H8

Canine B7-H4 Protein, His Tag (MALS verified)

分子别名(Synonym)

B7-H4,VTCN1,B7S1,B7h.5

表达区间及表达系统(Source)

Canine B7-H4, His Tag (B74-C52H8) is expressed from human 293 cells (HEK293). It contains AA Phe 29 - Ala 258 (Accession # XP_038547815.1).

Predicted N-terminus: Phe 29

Request for sequence

蛋白结构(Molecular Characterization)

B7-H4 Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 27.2 kDa. The protein migrates as 44-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

B7-H4 SDS-PAGE

Canine B7-H4, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS

B7-H4 SEC-MALS

The purity of Canine B7-H4, His Tag (Cat. No. B74-C52H8) is more than 95% and the molecular weight of this protein is around 38-50 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

B7-H4 ELISA

Immobilized Monoclonal Anti-Human B7-H4 Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Canine B7-H4, His Tag (Cat. No. B74-C52H8) with a linear range of 1-16 ng/mL (QC tested).

Protocol

B7-H4 ELISA

Immobilized Canine B7-H4, His Tag (Cat. No. B74-C52H8) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H4 Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-SPR

B7-H4 SPR

Anti-B7-H4 antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Canine B7-H4, His Tag (Cat. No. B74-C52H8) with an affinity constant of 8.59 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.

 

前沿进展

Targeting novel immune checkpoints in the B7-H family: advancing cancer immunotherapy from bench to bedside
Luo, Yuan, Liu et al
Trends Cancer (2025)
Abstract: The B7-H family of immune checkpoint molecules is a crucial component of the immune regulatory network for tumors, offering new opportunities to modulate the tumor microenvironment (TME). The B7-H family - which includes B7-H2 (inducible T cell costimulatory ligand, ICOSL), B7-H3, B7-H4, B7-H5 (V-domain immunoglobulin suppressor of T cell activation, VISTA), B7-H6, and B7-H7 (HHLA2) - is known for its diverse roles in regulating innate and adaptive immunity. These molecules can exhibit co-stimulatory or co-inhibitory effects on T cells, influencing processes such as T cell activation, differentiation, and effector functions, and they are involved in the recruitment and polarization of various immune cells. This review explores the structural characteristics, receptor-ligand interactions, and signaling pathways associated with each B7-H family member. We also discuss the family's impact on tumor immunity and potential therapeutic strategies.Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review
Yamanaka, Nishikawa, Yoshida
Cells (2025) 14 (5)
Abstract: Despite recent advances in cancer treatment, the prognosis for uterine malignancies (carcinoma and sarcoma) requires further improvement. Antibody-drug conjugates (ADCs) have emerged as a novel class of anti-cancer therapeutic agents, and multiple ADCs have been approved for other types of cancer. In 2024, trastuzumab deruxtecan received approval from the US Food and Drug Administration for cancer types and became the first ADC approved for the treatment of uterine malignancies. Many ADCs are currently being investigated in uterine malignancies, and therefore, there is a need to gain a deeper understanding of ADCs. In this article, we aim to provide a comprehensive overview of the advancements in ADCs. The contents of this article include the structure and mechanism of action, an analysis of recent clinical trials, and expected future clinical questions. This article also focuses on uterine sarcoma, which is not often highlighted as a target for ADC treatment.
A mini-overview of antibody-drug conjugates in platinum-resistant ovarian cancer: A preclinical and clinical perspective
Zhao, Yuan, Li et al
Int J Biol Macromol (2025) 304 (Pt 2), 140767
Abstract: Ovarian cancer is one of the most lethal gynaecologic cancers in China. Although platinum-based chemotherapy, PARP inhibitors and bevacizumab have prolonged long term survival and increased the overall response rate for platinum-sensitive ovarian cancer (PSOC), the treatment options for platinum-resistant ovarian cancer (PROC) are still limited. Antibody-drug conjugates (ADCs) represent a novel form of precision medicine, covalently linking specific monoclonal antibodies with potent cytotoxic payloads. Since mirvetuximab soravtansine (MIRV) received approval by the US Food and Drug Administration (FDA) as the first ADC for PROC in 2022, the development of novel ADCs for various targets in PROC has accelerated. In this review, we summarise the recent evidence and future prospects of ADCs targeting Folate Receptor alpha (FRα), mesothelin, cadherin-6, NaPi2b, human epidermal growth factor receptor 2 (HER2), dipeptidase 3 (DPEP3), B7-H4 (VTCN1), claudin-6 (CLDN6) and trophoblast antigen protein 2 (TROP2), in order to enhance our understanding of the clinical applications of ADCs and offer new insights for clinical practice and further research.Copyright © 2025. Published by Elsevier B.V.
Exploring B7-H4's role in prostate cancer dormancy post-androgen deprivation therapy: extracellular matrix interactions and therapeutic opportunities
Kang, Xue, Wong et al
Mol Cancer Res (2025)
Abstract: Prostate cancer (PCa) is mainly managed with androgen deprivation therapy (ADT), but this often leads to a dormant state and subsequent relapse as lethal castration-resistant prostate cancer (CRPC). Using our unique PCa patient-derived xenograft (PDX) dormancy models, we investigated this critical dormant phase and discovered a selective increase in B7-H4 expression during the dormancy period following mouse host castration. This finding is supported by observations in clinical specimens of PCa patients treated with ADT. Differential expression analyses revealed the enrichment of extracellular matrix (ECM)-cell interaction pathways in B7-H4-positive cells. Functional assays demonstrated a crucial role of B7-H4 in maintaining dormancy within the ECM niche. Specifically, B7-H4 expression in LNCaP cells reduced proliferation within dormant ECM in vitro and significantly delayed relapse in castrated hosts in vivo. These results shed light on the dynamic regulation of B7-H4 during PCa dormancy and underscore its potential as a therapeutic target for preventing CRPC relapse. Implications: Our study identified membranous B7-H4 expression during ADT-induced dormancy, highlighting its potential as a therapeutic target for managing dormant prostate cancer and preventing fatal CRPC relapse.
Showing 1-4 of 505 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
B7-H4靶点信息
英文全称:V-set domain-containing T-cell activation inhibitor 1
中文全称:含V区域T细胞激活抑制因子1
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:9详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定